Corrector-mediated rescue of misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump

Biochemical Pharmacology

Volumn 83, Issue 3, 2012, Pages 345-354

  Loo, Tip W ^a   Bartlett, M Claire ^a   Shi, Li ^a   Clarke, David M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

CFTR; Corrector; Cystic fibrosis; P glycoprotein; Pharmacological chaperone; Protein stability

Indexed keywords

4,5,7 TRIMETHYL N PHENYLQUINOLIN 2 AMINE; 7 CHLORO 4 [4 (4-CHLOROPHENYLSULFONYL)PIPERAZIN 1 YL]QUINOLINE; ADENOSINE TRIPHOSPHATASE; CHAPERONE; GLYCOPROTEIN P; KM 11060; LUMACAFTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOAVAILABILITY; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE MUTATION; HUMAN; LOW TEMPERATURE PROCEDURES; MUTANT; NONHUMAN; PREDICTION; PRIORITY JOURNAL;

ANIMALS; BENZBROMARONE; CELL LINE; CRICETINAE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HEK293 CELLS; HUMANS; MESOCRICETUS; MUTATION; P-GLYCOPROTEIN; RNA PROCESSING, POST-TRANSCRIPTIONAL; SUBSTRATE SPECIFICITY;

EID: 84455208061     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.11.014     Document Type: Article

References (62)

1. J.R. Riordan CFTR function and prospects for therapy Annu Rev Biochem 77 2008 701 726
2. M.J. Welsh, and A.E. Smith Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis Cell 73 1993 1251 1254 (Pubitemid 23201140)
3. J.R. Riordan, J.M. Rommens, B. Kerem, N. Alon, R. Rozmahel, and Z. Grzelczak Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA Science 245 1989 1066 1073 (Pubitemid 19231814)
4. C.M. Farinha, and M.D. Amaral Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin Mol Cell Biol 25 2005 5242 5252 (Pubitemid 40781121)
5. S.H. Cheng, R.J. Gregory, J. Marshall, S. Paul, D.W. Souza, and G.A. White Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis Cell 63 1990 827 834 (Pubitemid 120035055)
6. S.M. Rowe, S. Miller, and E.J. Sorscher Cystic fibrosis N Engl J Med 352 2005 1992 2001 (Pubitemid 40638370)
7. M.D. Amaral, and K. Kunzelmann Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis Trends Pharmacol Sci 28 2007 334 341 (Pubitemid 47016687)
8. G.M. Denning, M.P. Anderson, J.F. Amara, J. Marshall, A.E. Smith, and M.J. Welsh Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive Nature 358 1992 761 764
9. S. Sato, C.L. Ward, M.E. Krouse, J.J. Wine, and R.R. Kopito Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation J Biol Chem 271 1996 635 638 (Pubitemid 26034907)
10. X.M. Zhang, X.T. Wang, H. Yue, S.W. Leung, P.H. Thibodeau, and P.J. Thomas Organic solutes rescue the functional defect in delta F508 cystic fibrosis transmembrane conductance regulator J Biol Chem 278 2003 51232 51242 (Pubitemid 38020360)
11. M.E. Egan, J. Glockner-Pagel, C. Ambrose, P.A. Cahill, L. Pappoe, and N. Balamuth Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells Nat Med 8 2002 485 492 (Pubitemid 34546751)
12. C. Norez, S. Noel, M. Wilke, M. Bijvelds, H. Jorna, and P. Melin Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat FEBS Lett 580 2006 2081 2086
13. N. Vij, S. Fang, and P.L. Zeitlin Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications J Biol Chem 281 2006 17369 17378
14. M. Sharma, F. Pampinella, C. Nemes, M. Benharouga, J. So, and K. Du Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes J Cell Biol 164 2004 923 933 (Pubitemid 38366903)
15. E.M. Leslie, R.G. Deeley, and S.P. Cole Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense Toxicol Appl Pharmacol 204 2005 216 237 (Pubitemid 40552845)
16. T.W. Loo, M.C. Bartlett, and D.M. Clarke Benzbromarone stabilizes DeltaF508 CFTR at the cell surface Biochemistry 50 2011 4393 4395
17. A.W. Serohijos, T. Hegedus, A.A. Aleksandrov, L. He, L. Cui, and N.V. Dokholyan Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function Proc Natl Acad Sci USA 105 2008 3256 3261 (Pubitemid 351723540)
18. T. Diena, R. Melani, E. Caci, N. Pedemonte, E. Sondo, and O. Zegarra-Moran Block of CFTR-dependent chloride currents by inhibitors of multidrug resistance-associated proteins Eur J Pharmacol 560 2007 127 131 (Pubitemid 46341315)
19. T.W. Loo, and Clarke D.M. P-glycoprotein. Associations between domains and between domains and molecular chaperones J Biol Chem 270 1995 21839 21844
20. E.Y. Chen, M.C. Bartlett, T.W. Loo, and D.M. Clarke The ΔF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator J Biol Chem 279 2004 39620 39627 (Pubitemid 39258229)
21. T.A. Kunkel Rapid and efficient site-specific mutagenesis without phenotypic selection Proc Natl Acad Sci USA 82 1985 488 492 (Pubitemid 15128292)
22. T.W. Loo, M.C. Bartlett, and D.M. Clarke Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR) J Biol Chem 283 2008 28190 28197
23. O. Kalid, M. Mense, S. Fischman, A. Shitrit, H. Bihler, and E. Ben-Zeev Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening J Comput Aided Mol Des 24 2010 971 991
24. H.M. Sampson, R. Robert, J. Liao, E. Matthes, G.W. Carlile, and J.W. Hanrahan Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR Chem Biol 18 2011 231 242
25. F. Van Goor, S. Hadida, P.D. Grootenhuis, B. Burton, J.H. Stack, and K.S. Straley Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 Proc Natl Acad Sci USA 108 2011 18843 18848
26. T.W. Loo, M.C. Bartlett, and D.M. Clarke Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments Biochemistry 46 2007 9328 9336 (Pubitemid 47255045)
27. R. Robert, G.W. Carlile, C. Pavel, N. Liu, S.M. Anjos, and J. Liao Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect Mol Pharmacol 73 2008 478 489 (Pubitemid 351159218)
28. T.W. Loo, M.C. Bartlett, and D.M. Clarke The V510D suppressor mutation stabilizes DeltaF508-CFTR at the cell surface Biochemistry 49 2010 6352 6357
29. T.W. Loo, and D.M. Clarke Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities J Biol Chem 270 1995 21449 21452
30. S. Chifflet, A. Torriglia, R. Chiesa, and S. Tolosa A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPases Anal Biochem 168 1988 1 4 (Pubitemid 18088291)
31. T.W. Loo, M.C. Bartlett, and D.M. Clarke Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments J Biol Chem 277 2002 27585 27588 (Pubitemid 34966699)
32. T.W. Loo, and D.M. Clarke Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators J Biol Chem 272 1997 709 712 (Pubitemid 27034553)
33. N. Pedemonte, G.L. Lukacs, K. Du, E. Caci, O. Zegarra-Moran, and L.J. Galietta Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening J Clin Invest 115 2005 2564 2571 (Pubitemid 41266219)
34. F. Van Goor, K.S. Straley, D. Cao, J. Gonzalez, S. Hadida, and A. Hazlewood Rescue of ΔF508 CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules Am J Physiol Lung Cell Mol Physiol 290 2006 L1117 L1130
35. G.W. Carlile, R. Robert, D. Zhang, K.A. Teske, Y. Luo, and J.W. Hanrahan Correctors of protein trafficking defects identified by a novel high-throughput screening assay Chembiochem 8 2007 1012 1020 (Pubitemid 47189285)
36. T.W. Loo, M.C. Bartlett, and D.M. Clarke Rescue of ΔF508 and other misprocessed CFTR mutants by a novel quinazoline compound Mol Pharm 2 2005 407 413 (Pubitemid 41503681)
37. T.W. Loo, M.C. Bartlett, and D.M. Clarke Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains J Biol Chem 279 2004 38395 38401 (Pubitemid 39295989)
38. K. Varga, R.F. Goldstein, A. Jurkuvenaite, L. Chen, S. Matalon, and E.J. Sorscher Enhanced cell surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator by pharmacological chaperones Biochem J 410 2008 555 564 (Pubitemid 351429026)
39. S.M. Rowe, L.C. Pyle, A. Jurkevante, K. Varga, J. Collawn, and P.A. Sloane DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers Pulm Pharmacol Ther 23 2010 268 278
40. N. Pedemonte, V. Tomati, E. Sondo, and L.J. Galietta Influence of cell background on pharmacological rescue of mutant CFTR Am J Physiol Cell Physiol 298 2010 C866 C874
41. A. Jurkuvenaite, L. Chen, R. Bartoszewski, R. Goldstein, Z. Bebok, and S. Matalon Functional stability of rescued delta F508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells Am J Respir Cell Mol Biol 42 2010 363 372
42. D.E. Grove, M.F. Rosser, H.Y. Ren, A.P. Naren, and D.M. Cyr Mechanisms for rescue of correctable folding defects in CFTRDelta F508 Mol Biol Cell 20 2009 4059 4069
43. R.A. Caldwell, D.E. Grove, S.A. Houck, and D.M. Cyr Increased folding and channel activity of a rare cystic fibrosis mutant with CFTR modulators Am J Physiol Lung Cell Mol Physiol 301 2011 L346 L352
44. Y. Wang, M.C. Bartlett, T.W. Loo, and D.M. Clarke Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones Mol Pharmacol 70 2006 297 302
45. T.W. Loo, M.C. Bartlett, and D.M. Clarke Methanethiosulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites J Biol Chem 278 2003 50136 50141 (Pubitemid 37548851)
46. M.K. Gannon, J.J. Holt, S.M. Bennett, B.R. Wetzel, T.W. Loo, and M.C. Bartlett Rhodamine inhibitors of P-glycoprotein: an amide/thioamide switch for ATPase activity J Med Chem 52 2009 3328 3341
47. T.W. Loo, and D.M. Clarke The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface J Biol Chem 274 1999 24759 24765
48. C.L. Yoo, G.J. Yu, B. Yang, L.I. Robins, A.S. Verkman, and M.J. Kurth 4′-Methyl-4,5′-bithiazole-based correctors of defective delta F508-CFTR cellular processing Bioorg Med Chem Lett 18 2008 2610 2614 (Pubitemid 351503887)
49. P.H. Thibodeau, J.M. Richardson 3rd, W. Wang, L. Millen, J. Watson, and J.L. Mendoza The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis J Biol Chem 285 2010 35825 35835
50. Z. Shi, A.K. Tiwari, S. Shukla, R.W. Robey, S. Singh, and I.W. Kim Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance Cancer Res 71 2011 3029 3041
51. J.P. Clancy, S.M. Rowe, F.J. Accurso, M.L. Aitken, R.S. Amin, and M.A. Ashlock Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation Thorax 2011
52. D.F. Tang-Wai, S. Kajiji, F. DiCapua, D. de Graaf, I.B. Roninson, and Gros P. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators Biochemistry 34 1995 32 39
53. L. Wellhauser, P. Kim Chiaw, S. Pasyk, C. Li, M. Ramjeesingh, and C.E. Bear A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability Mol Pharmacol 75 2009 1430 1438
54. M.F. Rosser, D.E. Grove, L. Chen, and D.M. Cyr Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2 Mol Biol Cell 19 2008 4570 4579
55. K. Enquist, M. Fransson, C. Boekel, I. Bengtsson, K. Geiger, and L. Lang Membrane-integration characteristics of two ABC transporters, CFTR and P-glycoprotein J Mol Biol 387 2009 1153 1164
56. A.G. Therien, F.E. Grant, and C.M. Deber Interhelical hydrogen bonds in the CFTR membrane domain Nat Struct Biol 8 2001 597 601 (Pubitemid 32613007)
57. N. Pedemonte, V. Tomati, E. Sondo, E. Caci, E. Millo, and A. Armirotti Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations J Biol Chem 286 2011 15215 15226
58. P.W. Phuan, B. Yang, J.M. Knapp, A.B. Wood, G.L. Lukacs, and M.J. Kurth Cyanoquinolines with independent corrector and potentiator activities restore {delta}phe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis Mol Pharmacol 80 2011 683 693
59. C. Globisch, I.K. Pajeva, and M. Wiese Identification of putative binding sites of P-glycoprotein based on its homology model ChemMedChem 3 2008 280 295
60. W.L. DeLano The PyMol Molecular Graphics System 2002 DeLano Scientific Palo Alto, CA, USA http://www.pymol.org
61. M. Mense, P. Vergani, D.M. White, G. Altberg, A.C. Nairn, and D.C. Gadsby In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer EMBO J 25 2006 4728 4739 (Pubitemid 44607019)
62. T.W. Loo, and D.M. Clarke Drug-stimulated ATPase activity of human P-glycoprotein is blocked by disulfide cross-linking between the nucleotide-binding sites J Biol Chem 275 2000 19435 19438 (Pubitemid 30441531)